VCN Biosciences:

Highly selective viruses specifically designed
to treat refractory tumors

VCN Biosciences:

The company developing the next generation
of oncolytic adenovirus
Our oncolytic adenoviruses are designed
to obtain clinical activity by systemic administration
Slider

VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.

 

News

VCN Biosciences Announces Publication in Peer-Reviewed Journal of Controlled Release of Preclinical Research on an Oncolytic Adenovirus with Hyaluronidase Activity that Evades Neutralizing Antibodies

Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.

Read more ...
VCN Biosciences Announces a Dose Escalation of VCN-01 in combination with Durvalumab in Phase I Clinical Trial in Head and Neck Carcinoma

Barcelona, February 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced that VCN-01 at a dose of 3.3x1012 vp/patient can be safely administered in combination with Durbalumab when administered 15 days apart. Accordingly, in an Investigator Meeting, it was decided that VCN-01 will be further investigated at a higher dose of 1x1013 vp/patient in combination with Durvalumab.

Read more ...
Child beats retinal cancer thanks to a world-first treatment based on an oncolytic virus

Barcelona, November 27, 2020 – A team of researchers from SJD BarcelonaA team of researchers from SJD BarcelonaChildren’s Hospital and the biotechnology company VCN Biosciences, a Grifols company,has developed a world-first treatment which has prevented a child, who hadalready lost an eye to retinal cancer, from losing the other eye and becomingcompletely blind. As a result, Félix, who travelled from Venezuela to Barcelonaspecifically for the treatment, is now disease-free and retains his visual acuity, allowinghim to walk and play just as before. The treatment, which was administered as part ofa clinical trial, consists in injecting a genetically modified virus into the tumour-affectedeye. This virus can select, attack and destroy cancer cells.

Read more ...
VCN Biosciences to present data with VCN-01 in patients with pancreatic cancer at ESMO 2019.

September 3, 2019 –VCN Biosciences, a clinical–stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtainedwith its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September –1 October2019.

Read more ...